Your PFA jacket material has full ISO 10993 supplier data. Your cable still might fail biocompatibility testing.
That sentence is the single most expensive lesson we see medical device teams learn. They specify a "biocompatible cable" by listing materials with known biocompatibility data — PFA jacket, PTFE dielectric, silver-plated copper conductor, FEP heat-shrink — and assume the assembly inherits that data. It does not. The finished ISO 10993 biocompatible cable is a different physical object than its raw materials, and ISO 10993-1:2018 is explicit that biological evaluation applies to the finished medical device or component as it contacts the patient.
This post walks through the four biggest myths cable buyers carry into ISO 10993 conversations, what the actual reality looks like, and how to write a cable spec that will pass biocompatibility testing the first time. We've supported dozens of medical device programs through ISO 10993 panels — including a few that failed first-round and had to be reworked — and the patterns are consistent.
Myth 1: "If my materials are biocompatible, my cable is biocompatible."
This is the foundational misunderstanding. The biocompatibility of the finished assembly depends on processing as much as on materials.
Consider a typical micro coaxial cable assembly with a marked outer jacket. The PFA jacket polymer has clean ISO 10993-5 cytotoxicity data from the resin supplier. But the cable goes through:
- Extrusion at 350-380°C, which can introduce thermal degradation byproducts if the line wasn't purged correctly
- Laser marking, which leaves carbonized polymer residue at the surface and may introduce trace metal contamination from the marking ink if a non-validated ink is used
- Termination with solder flux — even a "no-clean" flux residue can show cytotoxicity at the levels typically present after assembly
- Adhesive backfill at the connector strain relief, which may use a non-medical adhesive in a "non-contacting" location that turns out to leach through during extraction testing
- Final cleaning with isopropanol — and any residue from that, plus any contamination picked up during handling
Any of these can cause the finished assembly to fail cytotoxicity testing even though every raw material individually passes. The most common failure mode we see is solder flux residue. The second most common is marking ink. Both are processing issues, not material issues.
Reality : Specify cable manufacturers who do biocompatibility-aware processing — controlled extrusion lines, validated marking inks, medical-grade flux removal, documented cleaning protocols. Then test the finished assembly. At FRS Technology our medical assembly cell uses ink and flux systems pre-qualified to ISO 10993-5 and 10993-10, but we still test every new finished design because processing variables can shift outcomes.
Myth 2: "Cytotoxicity is the only test that matters."
Cytotoxicity (ISO 10993-5) is usually the first test run because it's relatively fast (about 4 weeks) and inexpensive (around $3,000-5,000). It uses an L929 mouse fibroblast cell culture and assesses whether extracts from your cable kill or damage cells. Pass this and you've cleared the basic toxicity gate.
But for cable assemblies that contact mucosal membranes, blood, or breached skin, a passing cytotoxicity result is necessary but nowhere near sufficient. The full ISO 10993-1 risk-based assessment may require:
- Sensitization (ISO 10993-10) : Does prolonged contact cause an allergic immune response? Tested via guinea pig maximization test or murine LLNA. About 6-8 weeks.
- Irritation (ISO 10993-23, replacing the older 10993-10 irritation portion) : Does the material irritate skin or mucosa on contact? Now uses reconstructed human epidermis models for many Applications .
- Chemical characterization (ISO 10993-18) : What chemicals actually leach from your cable? Done by GC-MS and LC-MS analysis of extracts. This is increasingly being required as a baseline before any biological testing, because regulators want to know what you're actually exposing the patient to.
- Hemocompatibility (ISO 10993-4) : For blood-contacting devices. Hemolysis, complement activation, thrombogenicity.
- Systemic toxicity (ISO 10993-11) : Does the device cause systemic effects via absorbed leachables? Acute, subacute, subchronic, or chronic depending on contact duration.
The ISO 10993-1 risk matrix maps device contact category (surface vs external communicating vs implant) and contact duration (limited <24h, prolonged 24h to 30 days, permanent >30 days) to required tests. Skipping a required test because "we tested cytotoxicity and it passed" is a common path to a regulatory rejection.
For micro coaxial cables in IVUS catheters, for example, the cable is in indirect contact with circulating blood through a sealed catheter wall. That places it in external communicating, blood path indirect, with prolonged contact duration. Required panel: cytotoxicity, sensitization, irritation, hemocompatibility, and chemical characterization at minimum. Cytotoxicity alone won't get the device through. We've seen submissions sent back for additional testing 6-9 months after initial filing because the original test plan was scoped too narrowly — and 6-9 months of regulatory delay on a venture-funded device program is the kind of mistake that gets people fired.
Reality : Build your test panel from the ISO 10993-1 risk matrix, not from convenience. Cytotoxicity is the starting line, not the finish line.
Myth 3: "ISO 10993 is a one-time qualification."
This one bites teams later in the program lifecycle. They run a full biocompatibility panel during initial qualification, get the certificates, file the regulatory submission, go to production. Then 18 months later something changes — a connector vendor reformulates their housing resin, a flux supplier discontinues a product, a marking ink is replaced — and the "biocompatible" cable is no longer the same cable that was tested.
ISO 10993-1 requires biological evaluation throughout the device lifecycle. A material change, a process change, a supplier change to any biocompatibility-critical component triggers a reassessment. Sometimes that reassessment is just a paper exercise (the new material has equivalent biocompatibility data and the change can be justified by analogy). Other times it requires repeat testing.
The places this catches people:
- Connector overmold material changes (the molding compound on a Hirose or I-PEX connector body)
- Strain relief polymer reformulation
- Adhesive bonding agent supplier change
- Marking ink reformulation (very common — ink suppliers tweak formulations regularly)
- Flux supplier change or no-clean flux reformulation
- Cleaning solvent change (e.g., from one IPA grade to another)
Reality : Establish change-control discipline with your cable supplier. Lock the bill of materials including suppliers, sub-supplier part numbers, and process parameters. Require notification of any change to biocompatibility-critical inputs. This is one place ISO 13485 quality system discipline pays off — see our comparison of ISO 9001 vs ISO 13485 for what to look for in your supplier's QMS.
Myth 4: "Off-the-shelf biocompatible cables exist and I can just buy them."
Sort of, but probably not for your application. There are catalog cables with biocompatibility data — usually for surface-contact, intact-skin Applications , frequantly for ECG lead wire and patient monitoring. These have value when your application matches what was tested.
For most micro coaxial assemblies in catheters, endoscopes, intracardiac echocardiography, electrophysiology mapping, intravascular ultrasound — the contact category, duration, or geometry doesn't match any catalog product. You need finished-assembly biocompatibility testing on your specific design. The "biocompatible cable" you buy off a catalog passes biocompatibility only as constructed and tested. Cut it, terminate it, and integrate it into your device, and you've changed the device under test.
Reality : For purpose-built medical cable assemblies — which describes basically every diagnostic IVUS or EP catheter cable — plan to do finished-assembly testing on your design. The catalog data accelerates risk assessment for the raw materials but doesn't substitute for testing the actual product. FRS Technology maintains a library of materials with documented supplier biocompatibility data — saves time at the chemical characterization stage — but our standard recommendation is still finished-assembly testing for any patient-contacting design.
Common failure modes by ISO 10993 test
| Test | Most common failure mode | Root cause | Fix |
|---|---|---|---|
| Cytotoxicity (10993-5) | L929 cell viability <70% | Solder flux residue; marking ink; processing contamination | Validate flux removal; use medical-grade marking ink; controlled cleaning protocol |
| Cytotoxicity (10993-5) | Edge-of-pass result (70-80% viability) | Borderline material; trace plasticizer migration | Switch to known clean polymer grade; add post-extrusion conditioning |
| Sensitization (10993-10) | Guinea pig response at challenge | Adhesive monomer leaching; certain rubber accelerators | Switch adhesive class; eliminate latex-derived materials |
| Irritation (10993-23) | Erythema/edema in epidermal model | Surface roughness from processing; trace acidity | Surface conditioning; pH-neutralized cleaning protocol |
| Chemical characterization (10993-18) | Unidentified peaks in GC-MS extract | Trace processing aids; antioxidant migration; oligomer release | Identify peaks; toxicological risk assessment; substitute materials if non-clearable |
| Hemolysis (10993-4) | >5% hemolysis in extract test | Surface chemistry; ionic leachables; processing residue contacting blood path | Surface treatment review; extended cleaning; sometimes complete material substitution |
| Systemic toxicity (10993-11) | Body weight loss in test animals | Significant leachable load; cumulative exposure to low-level toxicants | Reduce extractables via material/process change; this is rarely fixable without redesign |
Honestly, the failures we see most often in medical cable assemblies are the top three rows of that table — cytotoxicity issues from processing residues. They're also the easiest to fix once you know what's causing them. Sensitization and chemical characterization failures usually require material changes and add 2-4 months to a program. Hemocompatibility and systemic toxicity failures often mean rethinking the architecture.
The pre-test checklist nobody gives you
Before you send samples to a biocompatibility lab, do this:
- Confirm the samples represent finished, fully-processed assemblies — not pre-cleaned, not specially prepared. The lab needs to test what the patient will contact.
- Send sufficient sample mass. Most extraction protocols require 60-120 cm² of surface area or 4-6 grams of material. Cable assemblies have low surface-area-to-mass ratios, so you may need 5-10 assemblies per test.
- Include the bill of materials, processing parameters, and cleaning protocol with the samples. If a result occurrs that's borderline, the lab will need this to help identify the cause.
- Pre-confirm the extraction conditions with the lab. Polar (saline) and non-polar (vegetable oil or sesame oil) extracts are standard, but extraction temperature and duration depend on the device contact type.
- Lock the design before testing. Any change between sample preparation and submission means the data may not apply to what you ship.
What's easy to overlook
Two things teams routinely miss until late in the program:
First, chemical characterization is moving to the front of the test sequence . ISO 10993-18:2020 effectively requires a chemical characterization data package as the basis for the biological risk assessment, and notified bodies are increasingly asking for it before they'll accept biological data alone. If you're planning a CE mark submission for a 2026 medical device, get your chemical characterization done early — it informs which biological tests you actually need.
Second, cleaning validation is part of biocompatibility . The cleaning protocol that produces the test samples must match the production cleaning protocol. If you test on lab-cleaned samples and ship production parts cleaned differently, you've introduced a gap in your biological evaluation. Document the production cleaning protocol explicitly, validate it, and use it on biocompatibility samples. The ISO 10993-1:2018 standard walks through the integrated risk-based approach in detail.
Third — and this catches teams who reuse a previously-tested cable in a new device — biocompatibility data is application-specific. Data generated for a 30-day surface-contact application doesn't automatically extend to a 90-day mucosal application even if the cable is physically identical. The risk assessment changes with contact category and duration, and the test requirements may change with it. Reusing a "biocompatible" cable across product lines is fine, as long as each product's biological evaluation justifies the reuse against that product's specific risk profile.
If you're scoping a biocompatibility test plan for a new cable assembly and want a sanity check before you commit to a $50,000 test panel, our medical engineering team can review your spec and flag the failure modes most likely to bite you. We've watched enough first-round failures to spot the warning signs in 30 minutes.
Related Products
FRS Technology manufactures custom multi-core micro coaxial cable assemblies from 4 to 512 cores, 36-50 AWG, phase-matched to +/-1%. Products related to this topic:
Contact us with your application requirements. We reply with a technical proposal and pricing within 48 hours.
